Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Anna M. Kamphuis"'
Autor:
Isabella A. J. van Duin, Sjoerd G. Elias, Alfonsus J. M. van den Eertwegh, Jan Willem B. de Groot, Willeke A. M. Blokx, Paul J. van Diest, Tim Leiner, Joost J. C. Verhoeff, Rik J. Verheijden, Olivier J. van Not, Maureen J. B. Aarts, Franchette W. P. J. van den Berkmortel, Christian U. Blank, John B. A. G. Haanen, Geke A. P. Hospers, Anna M. Kamphuis, Djura Piersma, Rozemarijn S. van Rijn, Astrid A. M. van der Veldt, Gerard Vreugdenhil, Michel W. J. M. Wouters, Marion A. M. Stevense‐den Boer, Marye J. Boers‐Sonderen, Ellen Kapiteijn, Karijn P. M. Suijkerbuijk
Publikováno v:
van Duin, I A J, Elias, S G, van den Eertwegh, A J M, de Groot, J W B, Blokx, W A M, van Diest, P J, Leiner, T, Verhoeff, J J C, Verheijden, R J, van Not, O J, Aarts, M J B, van den Berkmortel, F W P J, Blank, C U, Haanen, J B A G, Hospers, G A P, Kamphuis, A M, Piersma, D, van Rijn, R S, van der Veldt, A A M, Vreugdenhil, G, Wouters, M W J M, Stevense-den Boer, M A M, Boers-Sonderen, M J, Kapiteijn, E & Suijkerbuijk, K P M 2023, ' Time interval from primary melanoma to first distant recurrence in relation to patient outcomes in advanced melanoma ', International Journal of Cancer, vol. 152, no. 12, pp. 2493-2502 . https://doi.org/10.1002/ijc.34479
International Journal of Cancer, 152(12), 2493-2502. Wiley
International Journal of Cancer, 152(12), 2493-2502. Wiley-Liss Inc.
International Journal of Cancer, 152(12), 2493-2502. Wiley
International Journal of Cancer, 152(12), 2493-2502. Wiley-Liss Inc.
Since the introduction of BRAF(/MEK) inhibition and immune checkpoint inhibition (ICI), the prognosis of advanced melanoma has greatly improved. Melanoma is known for its remarkably long time to first distant recurrence (TFDR), which can be decades i
Autor:
Olivier J. van Not, Rik J. Verheijden, Alfonsus J. M. van den Eertwegh, John B. A. G. Haanen, Maureen J. B. Aarts, Franchette W. P. J. van den Berkmortel, Christian U. Blank, Marye J. Boers-Sonderen, Jan-Willem B. de Groot, Geke A. P. Hospers, Anna M. Kamphuis, Ellen Kapiteijn, Anne M. May, Melissa M. de Meza, Djura Piersma, Rozemarijn van Rijn, Marion A. Stevense-den Boer, Astrid A. M. van der Veldt, Gerard Vreugdenhil, Willeke A. M. Blokx, Michel J. M. Wouters, Karijn P. M. Suijkerbuijk
Publikováno v:
JAMA Oncology. AMER MEDICAL ASSOC
JAMA Oncology
JAMA Oncology, 8(12), 1794-1801. American Medical Association
van Not, O J, Verheijden, R J, van den Eertwegh, A J M, Haanen, J B A G, Aarts, M J B, van den Berkmortel, F W P J, Blank, C U, Boers-Sonderen, M J, de Groot, J-W B, Hospers, G A P, Kamphuis, A M, Kapiteijn, E, May, A M, de Meza, M M, Piersma, D, van Rijn, R, Stevense-den Boer, M A, van der Veldt, A A M, Vreugdenhil, G, Blokx, W A M, Wouters, M J M & Suijkerbuijk, K P M 2022, ' Association of Immune-Related Adverse Event Management with Survival in Patients with Advanced Melanoma ', JAMA Oncology, vol. 8, no. 12, pp. 1794-1801 . https://doi.org/10.1001/jamaoncol.2022.5041
JAMA oncology, 8(12), 1794-1801. AMER MEDICAL ASSOC
Jama Oncology, 8, 12, pp. 1794-1801
Jama Oncology, 8, 1794-1801
JAMA Oncology
JAMA Oncology, 8(12), 1794-1801. American Medical Association
van Not, O J, Verheijden, R J, van den Eertwegh, A J M, Haanen, J B A G, Aarts, M J B, van den Berkmortel, F W P J, Blank, C U, Boers-Sonderen, M J, de Groot, J-W B, Hospers, G A P, Kamphuis, A M, Kapiteijn, E, May, A M, de Meza, M M, Piersma, D, van Rijn, R, Stevense-den Boer, M A, van der Veldt, A A M, Vreugdenhil, G, Blokx, W A M, Wouters, M J M & Suijkerbuijk, K P M 2022, ' Association of Immune-Related Adverse Event Management with Survival in Patients with Advanced Melanoma ', JAMA Oncology, vol. 8, no. 12, pp. 1794-1801 . https://doi.org/10.1001/jamaoncol.2022.5041
JAMA oncology, 8(12), 1794-1801. AMER MEDICAL ASSOC
Jama Oncology, 8, 12, pp. 1794-1801
Jama Oncology, 8, 1794-1801
ImportanceManagement of checkpoint inhibitor–induced immune-related adverse events (irAEs) is primarily based on expert opinion. Recent studies have suggested detrimental effects of anti–tumor necrosis factor on checkpoint-inhibitor efficacy.Obje
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b26478643297b0e2ad8b55899ada18a
http://hdl.handle.net/1887/3564012
http://hdl.handle.net/1887/3564012
Autor:
Mick J. M. van Eijs, Lotte E. van der Wagen, Rogier Mous, Roos J. Leguit, Lisette van de Corput, Anne S. R. van Lindert, Britt B. M. Suelmann, Anna M. Kamphuis, Stefan Nierkens, Karijn P. M. Suijkerbuijk
Publikováno v:
Cancer immunology, immunotherapy : CII.
Immune checkpoint inhibition (ICI) can induce durable responses in patients with advanced malignancies. Three cases of hematological neoplasia following ICI for solid tumors have been reported to date. We present five patients treated at our tertiary
Publikováno v:
Journal of Clinical Pathology : the Journal of the Association of Clinical Pathologists, 73, 12
Journal of Clinical Pathology : the Journal of the Association of Clinical Pathologists, 73
Journal of Clinical Pathology : the Journal of the Association of Clinical Pathologists, 73
A 36-year-old woman presented with postprandial abdominal pain. Radiological assessment showed an irregular endoluminal mass in intrahepatic bile ducts and a separate mass in liver segment 8. A liver biopsy was performed. In addition, medical history